Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OMEGA HEALTHCARE INVESTORS INCOHI · Entity 3362 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OMEGA HEALTHCARE INVESTORS INC
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,931 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 3,778 · Balance 47,931 F1: Represents Director compensation granted on June 5, 2026 via a Restricted Stock Grant Award Agreement which will vest on the date of the Company's 2027 Annual Meeting of Shareholders, which is approximately one (1) year from the date of the grant and will convert to common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Director compensation granted on June 5, 2026 via a Restricted Stock Grant Award Agreement which will vest on the date of the Company's 2027 Annual Meeting of Shareholders, which is approximately one (1) year from the date of the grant and will convert to common stock on a one-for-one basis.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 1
1 source rowRow 1 · 2026-04-27 · Disposition to issuer · Disposed 118,598 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 98,184 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-27 · Disposition to issuer · Disposed 25,964 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 98,184 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3: Each Option was fully vested.
F4: Each Option vested in full in connection with consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 20:15 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | GrantCommon Stock | 3,778 | $43.67 | $164,985.26 |
DisclosureSEC source: 0001188191-26-000002 · form4-06092026_040634.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,931 F1 · shares: Represents Director compensation granted on June 5, 2026 via a Restricted Stock Grant Award Agreement which will vest on the date of the Company's 2027 Annual Meeting of Shareholders, which is approximately one (1) year from the date of the grant and will convert to common stock on a one-for-one basis. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 74,872 | Not disclosed Strike: $5.96 | Not disclosed |
DisclosureSEC source: 0001193125-26-182279 · ownership.xml · derivative · entry 8 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,872 shares Expires 2035-06-05 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4 · derivative.exercise_date: Each Option vested in full in connection with consummation of the Merger. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 42,467 | Not disclosed Strike: $10.27 | Not disclosed |
DisclosureSEC source: 0001193125-26-182279 · ownership.xml · derivative · entry 7 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,467 shares Expires 2034-06-06 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 30,474 | Not disclosed Strike: $12.62 | Not disclosed |
DisclosureSEC source: 0001193125-26-182279 · ownership.xml · derivative · entry 6 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,474 shares Expires 2033-06-08 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 45,423 | Not disclosed Strike: $8.55 | Not disclosed |
DisclosureSEC source: 0001193125-26-182279 · ownership.xml · derivative · entry 5 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,423 shares Expires 2032-06-09 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 36,111 | Not disclosed Strike: $10.71 | Not disclosed |
DisclosureSEC source: 0001193125-26-182279 · ownership.xml · derivative · entry 4 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,111 shares Expires 2031-06-10 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 18,574 | Not disclosed Strike: $12.81 | Not disclosed |
DisclosureSEC source: 0001193125-26-182279 · ownership.xml · derivative · entry 3 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,574 shares Expires 2030-06-04 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 25,964 | Not disclosed Strike: $12.00 | Not disclosed |
DisclosureSEC source: 0001193125-26-182279 · ownership.xml · derivative · entry 2 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,964 shares Expires 2029-06-27 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerCommon Stock | 118,598 | $14.50 | $1,719,671.00 |
DisclosureSEC source: 0001193125-26-182279 · ownership.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 98,184 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:05 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | GrantCommon Stock | 4,388 | $37.60 | $164,988.80 |
DisclosureSEC source: 0001415889-25-016461 · form4-06102025_040613.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,153 F1 · shares: Represents Director compensation granted on June 6, 2025 via a Restricted Stock Grant Award Agreement which will vest on the date of the Company's 2026 Annual Meeting of Shareholders, which is approximately one (1) year from the date of the grant and will convert to common stock on a one-for-one basis. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 74,872 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0000950170-25-083192 · ownership.xml · derivative · entry 2 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,872 Underlying: Common Stock · 74,872 shares Expires 2035-06-05 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 20,414 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083192 · ownership.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,598 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:06 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | GrantCommon Stock | 4,605 | $32.57 | $149,984.85 |
DisclosureSEC source: 0001415889-24-016349 · form4-06112024_080630.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,765 F1 · shares: Represents Director compensation granted on June 7, 2024 via a Restricted Stock Grant Award Agreement which will vest on the date of the Company's 2025 Annual Meeting of Shareholders, which is approximately one (1) year from the date of the grant and will convert to common stock on a one-for-one basis. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 23:54 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 42,467 | $0.00 Strike: $10.27 | $0.00 |
DisclosureSEC source: 0000950170-24-071010 · ownership.xml · derivative · entry 2 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,467 Underlying: Common Stock · 42,467 shares Expires 2034-06-06 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 23:54 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 11,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071010 · ownership.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,184 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:36 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 30,474 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001209191-23-036415 · doc4.xml · derivative · entry 2 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,474 Underlying: Common Stock · 30,474 shares Expires 2033-06-08 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:36 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 8,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036415 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,337 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 21:31 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | GrantCommon Stock | 4,995 | $30.03 | $149,999.85 |
DisclosureSEC source: 0001415889-23-009383 · form4-06072023_090615.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,160 F1 · shares: Represents Director compensation via the annual grant of restricted stock which will vest on the date of the Company's 2024 Annual Meeting of Shareholders, which is approximately one (1) year from date of grant. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:15 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 45,423 | $0.00 Strike: $8.55 | $0.00 |
DisclosureSEC source: 0001209191-22-035862 · doc4.xml · derivative · entry 2 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,423 Underlying: Common Stock · 45,423 shares Expires 2032-06-09 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:15 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 12,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035862 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,753 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 00:07 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | GrantCommon Stock | 5,131 | $29.23 | $149,979.13 |
DisclosureSEC source: 0001415889-22-006173 · form4-06062022_050629.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,165 F1 · shares: Represents Director compensation via the annual grant of restricted stock which will vest on the date of the Company's 2023 Annual Meeting of Shareholders, which is approximately one year from date of grant. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 22:31 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $10.49 | $15,735.00 |
DisclosureSEC source: 0001209191-21-062795 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,082 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $9.56 | $14,346.00 |
DisclosureSEC source: 0001209191-21-059153 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,582 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.45 to $9.58. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 16:54 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $33.65 | $16,825.00 |
DisclosureSEC source: 0001127602-21-024647 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,034 F1 · shares: This transaction was executed in a single block trade at $33.65. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| September 01, 2021 Filed Sep 7, 2021 22:53 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $11.41 | $17,115.00 |
DisclosureSEC source: 0001209191-21-055057 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,082 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 19:22 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $36.50 | $18,250.00 |
DisclosureSEC source: 0001127602-21-022727 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,534 F1 · shares: This transaction was executed in a single block trade at $36.50. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:12 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $9.28 | $13,920.00 |
DisclosureSEC source: 0001209191-21-049703 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,582 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 15:03 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $36.30 | $18,150.00 |
DisclosureSEC source: 0001127602-21-020924 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,034 F1 · shares: This transaction was executed in a single block trade at $36.30. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| July 01, 2021 Filed Jul 15, 2021 01:09 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $9.60 | $14,400.00 |
DisclosureSEC source: 0001209191-21-046712 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,082 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 23:08 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 36,111 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040381 · doc4.xml · derivative · entry 2 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,111 Underlying: Common Stock · 36,111 shares Expires 2031-06-10 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 23:08 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 10,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040381 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,582 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 19:41 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | GrantCommon Stock | 3,949 | $37.98 | $149,983.02 |
DisclosureSEC source: 0001127602-21-019505 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,534 F1 · shares: Represents Director compensation via the annual grant of restricted stock that will vest on the date of the Company's 2022 Annual Meeting of shareholders, which is approximately one year from grant date. Read SEC document |
| June 01, 2021 Filed Jun 1, 2021 16:02 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $36.96 | $18,480.00 |
DisclosureSEC source: 0001127602-21-018398 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,585 F1 · shares: This transaction was executed at an average weighted price of $36.96, with all trades within a dollar of the average. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, Omega Healthcare Investors, full information regarding the number of shares and prices at which the the transaction was effected. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:26 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $9.24 | $13,861.20 |
DisclosureSEC source: 0001209191-21-037394 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,467 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.22 to $9.46. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 4, 2021 17:43 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $38.16 | $19,080.00 |
DisclosureSEC source: 0001127602-21-015107 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,085 F1 · shares: This transaction was executed in a single block trade at $38.16. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $10.21 | $15,315.00 |
DisclosureSEC source: 0001209191-21-030440 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,967 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 16:20 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $37.08 | $18,540.00 |
DisclosureSEC source: 0001127602-21-012520 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,585 F1 · shares: This transaction was executed in a single block trade at $37.08. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:15 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $10.00 | $15,000.00 |
DisclosureSEC source: 0001209191-21-025365 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,467 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 01, 2021 Filed Mar 1, 2021 16:17 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $37.97 | $18,985.00 |
DisclosureSEC source: 0001127602-21-008213 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,085 F1 · shares: This transaction was executed in a single block trade at $37.97. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:58 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $12.40 | $18,600.00 |
DisclosureSEC source: 0001209191-21-017300 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,967 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 18:28 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $36.34 | $18,170.00 |
DisclosureSEC source: 0001127602-21-003204 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,585 F1 · shares: This transaction was executed in a single block trade at $36.34. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $19.09 | $28,636.80 |
DisclosureSEC source: 0001209191-21-007413 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,467 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $18.73 to $19.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 15:24 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $36.63 | $18,315.00 |
DisclosureSEC source: 0001127602-21-000018 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,085 F1 · shares: This transaction was executed in a single block trade at $36.63. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 00:31 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $23.17 | $34,755.00 |
DisclosureSEC source: 0001209191-21-001640 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,967 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 01, 2020 Filed Dec 1, 2020 19:03 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $36.10 | $18,050.00 |
DisclosureSEC source: 0001127602-20-030189 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,585 F1 · shares: This transaction was executed in a single block trade at $36.10. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:27 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $23.50 | $35,250.00 |
DisclosureSEC source: 0001209191-20-061632 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,467 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 18:37 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $28.96 | $14,480.00 |
DisclosureSEC source: 0001127602-20-027932 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,085 F1 · shares: This transaction was executed at an average weighted price of $28.96, with all trades within a dollar of the average. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, Omega Healthcare Investors, full information regarding the number of shares and prices at which the the transaction was effected. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 00:25 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $18.01 | $27,015.00 |
DisclosureSEC source: 0001209191-20-057019 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,967 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 19:28 UTC | OMEGA HEALTHCARE INVESTORS INC OHI · Entity 3362 | PurchaseCommon Stock | 500 | $29.97 | $14,985.00 |
DisclosureSEC source: 0001127602-20-026178 · form4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,585 F1 · shares: This transaction was executed in a single block trade at $29.97. This trade was executed pursuant to a 10b5-1 trading plan. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:12 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | PurchaseCommon Stock | 1,500 | $14.28 | $21,412.95 |
DisclosureSEC source: 0001209191-20-053735 · doc4.xml · nonDerivative · entry 1 WHITMAN BURKE W · CIK 0001188191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,467 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.24 to $14.30. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.